165 related articles for article (PubMed ID: 19017257)
21. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
Vandiver JW; Vondracek TG
Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
[TBL] [Abstract][Full Text] [Related]
23. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time: a rebuttal.
Kitchen S; Preston FE; Jennings I; Kitchen DP; Woods TA; Walker I
J Thromb Haemost; 2009 Dec; 7(12):2157-8; author reply 2178-9. PubMed ID: 19765209
[No Abstract] [Full Text] [Related]
24. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
Adatya S; Sunny R; Fitzpatrick MJ; Colvin M; Thennapan T; John R; Dodge Zantek N; Pritzker M; Eckman P; Uriel N
J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
[TBL] [Abstract][Full Text] [Related]
25. Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys.
Cuker A; Raby A; Moffat KA; Flynn G; Crowther MA
Thromb Haemost; 2010 Oct; 104(4):837-44. PubMed ID: 20664895
[TBL] [Abstract][Full Text] [Related]
26. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
[TBL] [Abstract][Full Text] [Related]
27. Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.
Mahmoud L; Zullo AR; McKaig D; Berard-Collins CM
R I Med J (2013); 2016 Mar; 99(3):33-7. PubMed ID: 26929970
[TBL] [Abstract][Full Text] [Related]
28. Challenges in variation and responsiveness of unfractionated heparin.
Francis JL; Groce JB;
Pharmacotherapy; 2004 Aug; 24(8 Pt 2):108S-119S. PubMed ID: 15334856
[TBL] [Abstract][Full Text] [Related]
29. Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms.
Whitman-Purves E; Coons JC; Miller T; DiNella JV; Althouse A; Schmidhofer M; Smith RE
Clin Appl Thromb Hemost; 2018 Mar; 24(2):310-316. PubMed ID: 29212374
[TBL] [Abstract][Full Text] [Related]
30. Protocolled Redefinition of the Therapeutic Range for Unfractionated Heparin: Lost in Translation?
Coene KLM; van der Graaf F; van de Kerkhof D
Clin Appl Thromb Hemost; 2018 Jan; 24(1):164-171. PubMed ID: 27856667
[TBL] [Abstract][Full Text] [Related]
31. Anti-activated factor II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study.
Hanslik A; Kitzmüller E; Tran US; Thom K; Karapetian H; Prutsch N; Voitl J; Michel-Behnke I; Newall F; Male C
J Thromb Haemost; 2017 Jan; 15(1):38-46. PubMed ID: 27736032
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic monitoring of unfractionated heparin - trials and tribulations.
Baluwala I; Favaloro EJ; Pasalic L
Expert Rev Hematol; 2017 Jul; 10(7):595-605. PubMed ID: 28632418
[TBL] [Abstract][Full Text] [Related]
33. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
34. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
[TBL] [Abstract][Full Text] [Related]
36. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
[TBL] [Abstract][Full Text] [Related]
37. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
38. From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.
May JE; Siniard RC; Taylor LJ; Marques MB; Gangaraju R
Am J Clin Pathol; 2022 Mar; 157(3):321-327. PubMed ID: 34562001
[TBL] [Abstract][Full Text] [Related]
39. Validation of high concentrated thrombin time assay for unfractionated heparin monitoring.
Apipongrat D; Police P; Lamool R; Butthep P; Chantkran W
J Clin Lab Anal; 2022 Oct; 36(10):e24695. PubMed ID: 36099012
[TBL] [Abstract][Full Text] [Related]
40. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
